When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
Authors
Keywords
-
Journal
Accountability in Research-Policies and Quality Assurance
Volume 20, Issue 4, Pages 227-269
Publisher
Informa UK Limited
Online
2013-06-28
DOI
10.1080/08989621.2013.793120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
- (2013) F. E. Vera-Badillo et al. ANNALS OF ONCOLOGY
- Proposed ‘Grant-And-Access’ Program With Price Caps Could Stimulate Development Of Drugs For Very Rare Diseases
- (2013) Ana M. Valverde et al. HEALTH AFFAIRS
- The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases
- (2012) L D Coles et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Orphan drug development: an economically viable strategy for biopharma R&D
- (2012) Kiran N. Meekings et al. DRUG DISCOVERY TODAY
- Australia makes up for lost time on rare diseases
- (2012) Tony Kirby LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Avastin loses breast cancer indication
- (2012) Karen Carey NATURE BIOTECHNOLOGY
- Pharmacogenomics in clinical practice and drug development
- (2012) Andrew R Harper et al. NATURE BIOTECHNOLOGY
- An Evaluation Framework for Funding Drugs for Rare Diseases
- (2012) Eric Winquist et al. VALUE IN HEALTH
- Pharmaceutical research and development: what do we get for all that money?
- (2012) D. W. Light et al. BMJ-British Medical Journal
- Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis
- (2012) Katherine E. Tansey et al. PLOS MEDICINE
- Outcomes of Emergency Department Patients Presenting With Adverse Drug Events
- (2011) Corinne M. Hohl et al. ANNALS OF EMERGENCY MEDICINE
- Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results
- (2011) M. Herder CANADIAN MEDICAL ASSOCIATION JOURNAL
- Despite Law, Fewer Than One In Eight Completed Studies Of Drugs And Biologics Are Reported On Time On ClinicalTrials.gov
- (2011) Michael R. Law et al. HEALTH AFFAIRS
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
- (2011) Aaron S. Kesselheim JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
- (2011) Francesco Trotta et al. JOURNAL OF CLINICAL ONCOLOGY
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation: Figure 1
- (2011) Wim Pinxten et al. JOURNAL OF MEDICAL ETHICS
- An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences
- (2011) AARON S. KESSELHEIM MILBANK QUARTERLY
- Biosimilars encircle Rituxan, US debates innovator exclusivity
- (2011) Karen Carey NATURE BIOTECHNOLOGY
- Pricing and reimbursement of orphan drugs: the need for more transparency
- (2011) Steven Simoens Orphanet Journal of Rare Diseases
- The Quality of Registration of Clinical Trials
- (2011) Roderik F. Viergever et al. PLoS One
- Role of patient and public participation in health technology assessment and coverage decisions
- (2011) Devidas Menon et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Economic Opportunities and Challenges for Pharmacogenomics
- (2010) Patricia A. Deverka et al. Annual Review of Pharmacology and Toxicology
- New approaches to rewarding pharmaceutical innovation
- (2010) P. Grootendorst et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Policy alternatives for treatments for rare diseases
- (2010) A. H. Panju et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Safety-Related Regulatory Actions for Orphan Drugs in the US and EU
- (2010) Harald E. Heemstra et al. DRUG SAFETY
- The Health Impact Fund: incentives for improving access to medicines
- (2010) Amitava Banerjee et al. LANCET
- Accelerating orphan drug development
- (2010) Timothy R. Coté et al. NATURE REVIEWS DRUG DISCOVERY
- Incentives for Drug Development — The Curious Case of Colchicine
- (2010) Aaron S. Kesselheim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Funding the Unfundable
- (2010) Tania Stafinski et al. PHARMACOECONOMICS
- Pivotal studies of orphan drugs approved for neurological diseases
- (2009) Jun Mitsumoto et al. ANNALS OF NEUROLOGY
- Federal committee to review appointment of Pfizer vice-president to CIHR governing council
- (2009) A. Silversides CANADIAN MEDICAL ASSOCIATION JOURNAL
- Translation of rare disease research into orphan drug development: disease matters
- (2009) Harald E. Heemstra et al. DRUG DISCOVERY TODAY
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
- (2009) Olivier Wellman-Labadie et al. HEALTH POLICY
- R&D policy, agency costs and innovation in personalized medicine
- (2009) Wesley Yin JOURNAL OF HEALTH ECONOMICS
- The microeconomics of personalized medicine: today's challenge and tomorrow's promise
- (2009) Jerel C. Davis et al. NATURE REVIEWS DRUG DISCOVERY
- Orphan products: an emerging trend in drug approvals
- (2009) Timothy Coté et al. NATURE REVIEWS DRUG DISCOVERY
- A Critique in Need of Critique
- (2009) M. Peterson et al. Public Health Ethics
- Two Ideas To Increase Innovation And Reduce Pharmaceutical Costs And Prices
- (2008) Arjun Jayadev et al. HEALTH AFFAIRS
- Engaging the public in priority-setting for health technology assessment: findings from a citizens’ jury
- (2008) Devidas Menon et al. HEALTH EXPECTATIONS
- The Benefits and Savings from Publicly Funded Clinical Trials of Prescription Drugs
- (2008) Dean Baker INTERNATIONAL JOURNAL OF HEALTH SERVICES
- Market incentives and pharmaceutical innovation
- (2008) Wesley Yin JOURNAL OF HEALTH ECONOMICS
- Does orphan drug legislation really answer the needs of patients?
- (2008) Marlene E Haffner et al. LANCET
- Incentives for orphan drug research and development in the United States
- (2008) Enrique Seoane-Vazquez et al. Orphanet Journal of Rare Diseases
- Poor Reporting of Scientific Leadership Information in Clinical Trial Registers
- (2008) Melanie Sekeres et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started